ReviewOncoTargets and therapy2022

Ovarian Cancer Therapy: Homologous Recombination Deficiency as a Predictive Biomarker of Response to PARP Inhibitors.

Rowan E Miller et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.